Stereotactic Radiosurgery and Systemic Dose Chemotherapy for Locally Advanced Lung Cancer

• Status: Unknown status
• Trial end date: 2017-10-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a pilot study looking at using stereotactic radiosurgery and full dose chemotherapy to treat stage II and III lung cancer that is not amendable to surgical resection.

• Phase: Early Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: The Cooper Health System
• Treatments: Albumin-Bound Paclitaxel; Carboplatin; Cisplatin; Docetaxel; Paclitaxel; Pemetrexed

Criteria

Inclusion criteria:

• Nonsmall cell lung cancer (NSCLC) (any histology)

• unresectable stage II

• Stage III

• Tumor less than 8 cm

• Karnofsky performance scale (KPS) of 50 or better

• Three or fewer mediastinal or hilar lymph nodes

Exclusion criteria

• Small cell lung cancer (SCLC)

• Stage I and stage IV patients

• Stage II patients eligible for surgical resection

• Concurrent severe disease that the treating physician feels will interfere with therapy this can include significant cardiovascular or pulmonary disease.

• KPS 40 or less (bed bound)

• Tumor size greater than 8 cm

• Inability to safely treat target lesions (at discretion of treating physician, this would most likely be secondary to not being able to place fiducial markers for tracking)

• Four or more medisatinal or hilar lymph nodes